Introduction:
The biosimilar market in Israel is rapidly growing, mirroring the global trend towards increased adoption of biosimilars. With a focus on innovation and cutting-edge research, Israel has emerged as a key player in the biosimilar development space. In 2026, the country is home to several major biosimilar developers who are making significant strides in the industry. The market for biosimilars in Israel is expected to continue expanding, driven by factors such as increasing demand for cost-effective biologic drugs and a favorable regulatory environment.
Top 50 Major Biosimilar Developers in Israel 2026:
1. Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. is a leading global pharmaceutical company based in Israel. With a strong focus on biosimilar development, Teva has established itself as a key player in the industry. The company’s biosimilar portfolio includes products targeting a range of therapeutic areas, such as oncology and autoimmune diseases.
2. Sandoz Israel
As a subsidiary of Novartis, Sandoz Israel is a major player in the biosimilar market. The company has a robust pipeline of biosimilar products and is known for its high-quality, cost-effective alternatives to biologic drugs. Sandoz Israel has a strong presence in both domestic and international markets.
3. Mylan Israel
Mylan Israel is a leading biosimilar developer with a diverse portfolio of products. The company’s biosimilars cover a wide range of therapeutic areas, including diabetes, oncology, and rheumatology. Mylan Israel is known for its commitment to quality and affordability in the biosimilar space.
4. Celltrion Israel
Celltrion Israel is a subsidiary of the South Korean biopharmaceutical company Celltrion, known for its expertise in biosimilar development. The company has a strong presence in the Israeli market and is actively expanding its footprint in the region. Celltrion Israel’s biosimilars are widely recognized for their efficacy and safety profiles.
5. Pfizer Israel
Pfizer Israel is a global pharmaceutical company with a significant presence in the biosimilar market. The company’s biosimilar portfolio includes products targeting various disease areas, such as oncology and immunology. Pfizer Israel is known for its innovative approach to biosimilar development and its commitment to delivering high-quality, affordable biologic alternatives.
Insights:
The biosimilar market in Israel is poised for continued growth in the coming years, driven by factors such as increasing healthcare expenditures and a growing demand for cost-effective biologic therapies. As major biosimilar developers in Israel continue to invest in research and development, the country is expected to play an increasingly important role in the global biosimilar landscape. With a favorable regulatory environment and a reputation for innovation, Israel is well-positioned to capitalize on the opportunities presented by the expanding biosimilar market. Overall, the future looks bright for biosimilar developers in Israel, as they continue to drive advancements in biologic drug development and improve access to high-quality, affordable therapies for patients worldwide.
Related Analysis: View Previous Industry Report
